Virtu Financial LLC boosted its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 307.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,233 shares of the biopharmaceutical company’s stock after purchasing an additional 6,968 shares during the quarter. Virtu Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $3,472,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in REGN. Harding Loevner LP boosted its stake in Regeneron Pharmaceuticals by 589.2% during the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after purchasing an additional 3,131,966 shares during the period. Old Mutual Global Investors UK Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 500,446.2% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock worth $145,472,000 after acquiring an additional 325,290 shares during the period. UBS Asset Management Americas Inc. lifted its position in shares of Regeneron Pharmaceuticals by 93.5% in the 4th quarter. UBS Asset Management Americas Inc. now owns 553,501 shares of the biopharmaceutical company’s stock worth $208,094,000 after acquiring an additional 267,442 shares during the period. Bank of Montreal Can lifted its position in shares of Regeneron Pharmaceuticals by 342.4% in the 4th quarter. Bank of Montreal Can now owns 188,828 shares of the biopharmaceutical company’s stock worth $70,991,000 after acquiring an additional 146,147 shares during the period. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $54,537,000. Hedge funds and other institutional investors own 65.89% of the company’s stock.
In related news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.80% of the company’s stock.
Regeneron Pharmaceuticals Inc (NASDAQ REGN) opened at $332.15 on Friday. Regeneron Pharmaceuticals Inc has a 52-week low of $313.53 and a 52-week high of $543.55. The company has a market capitalization of $35,685.86, a P/E ratio of 24.03, a P/E/G ratio of 1.04 and a beta of 1.47. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The firm had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.50 billion. During the same period last year, the firm posted $3.04 EPS. The business’s revenue was up 28.9% on a year-over-year basis. analysts forecast that Regeneron Pharmaceuticals Inc will post 19.2 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals Inc (REGN) Position Increased by Virtu Financial LLC” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2018/02/18/regeneron-pharmaceuticals-inc-regn-position-increased-by-virtu-financial-llc.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.